Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FBIO | US
-0.35
-13.46%
Healthcare
Biotechnology
31/03/2024
26/07/2024
2.25
2.60
2.60
2.24
Fortress Biotech Inc. a biopharmaceutical company develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101 an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302 an anti-GITR; CK-303 an anti-CAIX; and ONCOlogues and oligonucleotide platform. It has collaboration arrangements with universities research institutes and pharmaceutical companies. The company was formerly known as Coronado Biosciences Inc. and changed its name to Fortress Biotech Inc. in April 2015. Fortress Biotech Inc. was incorporated in 2006 and is based in Bay Harbor Islands Florida.
View LessPositive Momentum
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
109.4%1 month
89.3%3 months
68.5%6 months
74.3%-
-
1.52
3.85
0.54
-0.28
0.45
-0.10
-111.62M
45.93M
45.93M
-
-280.63
-
4.80
-1.74K
8.38
10.59
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.02
Range1M
1.29
Range3M
1.29
Rel. volume
1.80
Price X volume
1.15M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Reneo Pharmaceuticals Inc. Common Stock | RPHM | Biotechnology | 1.5 | 50.13M | 0.67% | n/a | 1.12% |
Akari Therapeutics Plc | AKTX | Biotechnology | 4.25 | 49.90M | 6.43% | n/a | 0.00% |
Atara Biotherapeutics Inc | ATRA | Biotechnology | 10.17 | 49.88M | 4.20% | n/a | -93.93% |
Lantern Pharma Inc. | LTRN | Biotechnology | 4.58 | 49.28M | 0.88% | n/a | 0.54% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.668 | 48.63M | 1.47% | n/a | 10.81% |
Marker Therapeutics Inc | MRKR | Biotechnology | 5.45 | 48.61M | 3.02% | n/a | 0.00% |
Common Stock | TARA | Biotechnology | 2.35 | 48.39M | 2.62% | n/a | 8.95% |
CALC | CALC | Biotechnology | 3.94 | 47.89M | 1.55% | 0.30 | 0.00% |
Fortress Biotech Inc | FBIOP | Biotechnology | 8.89 | 47.72M | -7.20% | n/a | 385.06% |
NextCure Inc | NXTC | Biotechnology | 1.64 | 45.88M | 3.80% | n/a | 6.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.9816 | 43.11M | -0.96% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 4.16 | 33.56M | 0.24% | n/a | 16.03% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.669 | 20.30M | 4.63% | n/a | 204.50% |
ILAG | ILAG | Building Products & Equipment | 0.8149 | 14.72M | -3.56% | n/a | 5.48% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6489 | 6.18M | 19.99% | n/a | 18.43% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4501 | 5.75M | 0.13% | n/a | 0.00% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.3324 | 5.24M | -0.72% | n/a | 1.80% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.61 | 4.11M | -1.23% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0135 | 1.01M | -2.88% | n/a | -2.20% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.28 | -2.85 | Expensive |
Ent. to Revenue | 0.45 | 4,050.30 | Cheaper |
PE Ratio | - | 39.84 | - |
Price to Book | 1.52 | 22.96 | Cheaper |
Dividend Yield | - | 1.79 | - |
Std. Deviation (3M) | 68.49 | 75.85 | Par |
Debt to Equity | 3.85 | 0.55 | Expensive |
Debt to Assets | 0.54 | 0.24 | Expensive |
Market Cap | 45.93M | 3.61B | Emerging |